Agmatine Sulfate is a supplement being used by weightlifters and anti-aging fanatics that among is benefits is relief from some neuropathic pain, it helps fights stress and depression. As an added benefit for diabetics it help reduce blood glucose levels and glycation of proteins(AGE's). Is also neuroprotective it may help memory preservation, is an aid for exercise and is anti-aging at least in rats. If you need help in any of this areas it may be something you can investigate.
http://www.mc.edu/faculty/files/7813/7823/8539/Agmatine-DDT_Final_Proofs_DRUDIS_1291_08-02-13.pdf
(Study below is by one of the supplement providers)
http://www.neurology.org/content/82/10_Supplement/P7.094.short
Abstract
OBJECTIVE:To evaluate the effect of agmatine sulfate on neuropathic painBACKGROUND:Neuropathic pain is common complaint of many patients especially diabetic patients, and current treatment is often not effective. Based on previous studies suggesting oral agmatine was a safe and effective treatment for sciatica we began a prospective study of the effect of Agmatine Sulfate, a decarboxylated arginine, on neuropathic pain.DESIGN/METHODS:Patients diagnosed with neuropathic pain were recruited into this study after a diagnosis of a small fiber neuropathy was confirmed by skin biopsy and/or quatitative sensorimotor axonal reflex testing (QSART). The Neuropathic Pain Questionnaire (Clinical Journal of Pain 19:306-314, 2003) was before started then monthly during a two month treatment period with agmatine sulfate (3.670 g/day), the nutraceutical salt of agmatine. This questionnaire includes 8 scales with positive correlations and 4 with negative correlations to neuropathic pain (i.e., a high score on the latter scales suggests a non-neuropathic pain). Patients were allowed the use of any concomitant conventional treatment during the study. QSART was also repeated at the end of the study. Statistical analyses were performed using student T-Test.
RESULTS:Five patients have completed the study to date. The only side effect was an unpleasant taste noted by a single patient that did not prevent finishing the study. T-test evaluation was done comparing the initial with the final answers. The Total Discriminant Function scores showed a significant decrease (p=0.03). The detailed categorization of neuropathic pain characteristics show significant decrease in burning (p=0.02), tingling (p=0.04) and unpleasant (p=0.02) aspects of the pain.
CONCLUSIONS:Our results in this ongoing study suggest that Agmatine Sulfate has a significant effect in decreasing burning, tingling and unpleasant aspects of neuropathic pain. It also has a statistical significant decrease in total Discriminant function score after two months of administration.Study Supported by:Gilad&Gilad
http://www.ncbi.nlm.nih.gov/pubmed/10984543
Abstract
Antagonists of glutamate receptors of the N-methyl-d-aspartate subclass (NMDAR) or inhibitors of nitric oxide synthase (NOS) prevent nervous system plasticity. Inflammatory and neuropathic pain rely on plasticity, presenting a clinical opportunity for the use of NMDAR antagonists and NOS inhibitors in chronic pain. Agmatine (AG), an endogenous neuromodulator present in brain and spinal cord, has both NMDAR antagonist and NOS inhibitor activities. We report here that AG, exogenously administered to rodents, decreased hyperalgesia accompanying inflammation, normalized the mechanical hypersensitivity (allodynia/hyperalgesia) produced by chemical or mechanical nerve injury, and reduced autotomy-like behavior and lesion size after excitotoxic spinal cord injury. AG produced these effects in the absence of antinociceptive effects in acute pain tests. Endogenous AG also was detected in rodent lumbosacral spinal cord in concentrations similar to those previously detected in brain. The evidence suggests a unique antiplasticity and neuroprotective role for AG in
processes underlying persistent pain and neuronal injury.
http://www.mc.edu/faculty/files/7813/7823/8539/Agmatine-DDT_Final_Proofs_DRUDIS_1291_08-02-13.pdf
(Study below is by one of the supplement providers)
http://www.neurology.org/content/82/10_Supplement/P7.094.short
Abstract
OBJECTIVE:To evaluate the effect of agmatine sulfate on neuropathic painBACKGROUND:Neuropathic pain is common complaint of many patients especially diabetic patients, and current treatment is often not effective. Based on previous studies suggesting oral agmatine was a safe and effective treatment for sciatica we began a prospective study of the effect of Agmatine Sulfate, a decarboxylated arginine, on neuropathic pain.DESIGN/METHODS:Patients diagnosed with neuropathic pain were recruited into this study after a diagnosis of a small fiber neuropathy was confirmed by skin biopsy and/or quatitative sensorimotor axonal reflex testing (QSART). The Neuropathic Pain Questionnaire (Clinical Journal of Pain 19:306-314, 2003) was before started then monthly during a two month treatment period with agmatine sulfate (3.670 g/day), the nutraceutical salt of agmatine. This questionnaire includes 8 scales with positive correlations and 4 with negative correlations to neuropathic pain (i.e., a high score on the latter scales suggests a non-neuropathic pain). Patients were allowed the use of any concomitant conventional treatment during the study. QSART was also repeated at the end of the study. Statistical analyses were performed using student T-Test.
RESULTS:Five patients have completed the study to date. The only side effect was an unpleasant taste noted by a single patient that did not prevent finishing the study. T-test evaluation was done comparing the initial with the final answers. The Total Discriminant Function scores showed a significant decrease (p=0.03). The detailed categorization of neuropathic pain characteristics show significant decrease in burning (p=0.02), tingling (p=0.04) and unpleasant (p=0.02) aspects of the pain.
CONCLUSIONS:Our results in this ongoing study suggest that Agmatine Sulfate has a significant effect in decreasing burning, tingling and unpleasant aspects of neuropathic pain. It also has a statistical significant decrease in total Discriminant function score after two months of administration.Study Supported by:Gilad&Gilad
http://www.ncbi.nlm.nih.gov/pubmed/10984543
Abstract
Antagonists of glutamate receptors of the N-methyl-d-aspartate subclass (NMDAR) or inhibitors of nitric oxide synthase (NOS) prevent nervous system plasticity. Inflammatory and neuropathic pain rely on plasticity, presenting a clinical opportunity for the use of NMDAR antagonists and NOS inhibitors in chronic pain. Agmatine (AG), an endogenous neuromodulator present in brain and spinal cord, has both NMDAR antagonist and NOS inhibitor activities. We report here that AG, exogenously administered to rodents, decreased hyperalgesia accompanying inflammation, normalized the mechanical hypersensitivity (allodynia/hyperalgesia) produced by chemical or mechanical nerve injury, and reduced autotomy-like behavior and lesion size after excitotoxic spinal cord injury. AG produced these effects in the absence of antinociceptive effects in acute pain tests. Endogenous AG also was detected in rodent lumbosacral spinal cord in concentrations similar to those previously detected in brain. The evidence suggests a unique antiplasticity and neuroprotective role for AG in
processes underlying persistent pain and neuronal injury.